At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
Azacitidine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC
In Brief
A Phase 2 clinical trial evaluating Azacitidine, Diagnostic Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Lung Non-Small Cell Carcinoma and Stage IV Lung Non-Small Cell Cancer AJCC v7. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This phase II clinical trial is studying how well azacitidine works in treating patients with previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionApr 2011
Study CompletionSep 2012
TodayJul 2026
First PostedJan 21, 2011
Enrollment StartJan 12, 2011
Primary CompletionApr 15, 2011
Study CompletionSep 12, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.4 years ago
Interventions
Azacitidinedrug
Given subcutaneously
Diagnostic Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies